Emerging treatments
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators
Early data suggest that the cystic fibrosis drug lumacaftor/ivacaftor may be of clinical use in LQT2 patients through its action on the hERG (human ether-a-go-go) gene trafficking defect affecting potassium channels.[5]
Use of this content is subject to our disclaimer